These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 28596160)

  • 1. Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.
    Yoshimoto T; Furuki T; Kobori H; Miyakawa M; Imachi H; Murao K; Nishiyama A
    J Investig Med; 2017 Oct; 65(7):1057-1061. PubMed ID: 28596160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poor glycemic control and decreased renal function are associated with increased intrarenal RAS activity in Type 2 diabetes mellitus.
    Nakatani S; Ishimura E; Naganuma T; Nakatani A; Ichii M; Fukumoto S; Mori K; Emoto M; Nakatani T; Inaba M
    Diabetes Res Clin Pract; 2014 Jul; 105(1):40-6. PubMed ID: 24846444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary angiotensinogen level is correlated with blood pressure level and proteinuria in patients with masked hypertension.
    Tiryaki O; Usalan C; Tarakcioglu M
    Clin Exp Hypertens; 2018; 40(7):644-649. PubMed ID: 29420088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
    Kawasoe S; Maruguchi Y; Kajiya S; Uenomachi H; Miyata M; Kawasoe M; Kubozono T; Ohishi M
    BMC Pharmacol Toxicol; 2017 Apr; 18(1):23. PubMed ID: 28391776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    J Pharmacol Sci; 2016 Jul; 131(3):198-208. PubMed ID: 27430987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
    Kurosaki E; Ogasawara H
    Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urinary angiotensinogen as a novel biomarker of the intrarenal renin-angiotensin system status in hypertensive patients.
    Kobori H; Alper AB; Shenava R; Katsurada A; Saito T; Ohashi N; Urushihara M; Miyata K; Satou R; Hamm LL; Navar LG
    Hypertension; 2009 Feb; 53(2):344-50. PubMed ID: 19075095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.
    Uzu T; Araki SI; Kashiwagi A; Haneda M; Koya D; Yokoyama H; Kida Y; Ikebuchi M; Nakamura T; Nishimura M; Takahara N; Obata T; Omichi N; Sakamoto K; Shingu R; Taki H; Nagai Y; Tokuda H; Kitada M; Misawa M; Nishiyama A; Kobori H; Maegawa H;
    PLoS One; 2016; 11(12):e0164936. PubMed ID: 28033332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis.
    Cai X; Yang W; Gao X; Chen Y; Zhou L; Zhang S; Han X; Ji L
    Obesity (Silver Spring); 2018 Jan; 26(1):70-80. PubMed ID: 29165885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells.
    Satou R; Cypress MW; Woods TC; Katsurada A; Dugas CM; Fonseca VA; Navar LG
    Am J Physiol Renal Physiol; 2020 Jan; 318(1):F67-F75. PubMed ID: 31682172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin-angiotensin-aldosterone system blockade in the kidney.
    van den Heuvel M; Batenburg WW; Jainandunsing S; Garrelds IM; van Gool JM; Feelders RA; van den Meiracker AH; Danser AH
    J Hypertens; 2011 Nov; 29(11):2147-55. PubMed ID: 21941204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
    Woods TC; Satou R; Miyata K; Katsurada A; Dugas CM; Klingenberg NC; Fonseca VA; Navar LG
    Am J Nephrol; 2019; 49(4):331-342. PubMed ID: 30921791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vitamin D receptor activation with calcitriol for reducing urinary angiotensinogen in patients with type 2 diabetic chronic kidney disease.
    Tiryaki Ö; Usalan C; Sayiner ZA
    Ren Fail; 2016; 38(2):222-7. PubMed ID: 26707134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary angiotensinogen excretion and ambulatory blood pressure.
    Zou J; Li Y; Li FH; Wei FF; Wang JG
    J Hypertens; 2012 Oct; 30(10):2000-6. PubMed ID: 22871893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased urinary angiotensinogen precedes the onset of albuminuria in normotensive type 2 diabetic patients.
    Zhuang Z; Bai Q; A L; Liang Y; Zheng D; Wang Y
    Int J Clin Exp Pathol; 2015; 8(9):11464-9. PubMed ID: 26617876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System.
    Ansary TM; Nakano D; Nishiyama A
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?
    Persson F; Lu X; Rossing P; Garrelds IM; Danser AH; Parving HH
    J Hypertens; 2013 Aug; 31(8):1646-52. PubMed ID: 23743807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice.
    Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
    Eur J Pharmacol; 2017 Aug; 809():163-171. PubMed ID: 28506912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in Urinary Angiotensinogen Associated with Deterioration of Kidney Function in Patients with Type 2 Diabetes Mellitus.
    Lee MJ; Kim SS; Kim IJ; Song SH; Kim EH; Seo JY; Kim JH; Kim S; Jeon YK; Kim BH; Kim YK
    J Korean Med Sci; 2017 May; 32(5):782-788. PubMed ID: 28378551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.